Skip to content
Peptide research

Tesamorelin

Also known as Egrifta
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
FDA-approved

A stabilized GHRH analog, FDA-approved to reduce visceral fat in HIV lipodystrophy, used off-label for fat loss, lipid gains, and GH restoration. Evidence is strong for those effects, muscle gains are modest, and cognitive benefit is only weakly supported. Injections often cause site reactions and joint aches, effects reverse once stopped, and a theoretical cancer risk from IGF-1 is unresolved. FDA-approved, though longevity use is off-label.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Egrifta (tesamorelin) is a synthetic 44-amino-acid version of growth hormone-releasing hormone (GHRH), the natural signal your brain sends to the pituitary gland to produce growth hormone. It has a chemical modification that protects it from being broken down too quickly in the body. Tesamorelin is the only FDA-approved medication specifically for reducing excess abdominal fat (lipodystrophy) in people living with HIV.

How it works in the body

A stabilized GHRH analog with a trans-3-hexenoic acid modification. It activates GHRH receptors on pituitary somatotrophs, producing physiological GH pulses. Specifically targeted at visceral adipose tissue — the deep abdominal fat linked to metabolic disease — reducing it without affecting subcutaneous fat or limb fat.

Research overview

Tesamorelin works by binding to GHRH receptors on the pituitary gland, stimulating your body's own natural pulsatile growth hormone release rather than replacing it with synthetic GH. This preserves the brain's normal feedback loop, which is a significant advantage over direct growth hormone injection. Clinical studies showed an 81% increase in IGF-1 levels (a marker of growth hormone activity). It is the only US-approved medication for HIV-associated lipodystrophy and has been extensively studied in Phase III trials. In the longevity space, it is of interest because it stimulates endogenous GH release, but it still carries risks from GH and IGF-1 elevation, including glucose intolerance and fluid retention. Its FDA approval is limited to the HIV indication.

Who researches Tesamorelin?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching visceral fat reduction

    One of the primary studied benefits of Tesamorelin.

Important considerations for

  • Those with Active malignancy

    Absolute

    FDA label: discontinue if active malignancy develops. GH promotes tumor growth.

  • Those who are pregnant or breastfeeding

    Absolute

    FDA label: can cause fetal harm based on mechanism of action.

  • Those with Disruption of hypothalamic-pituitary axis from surgery/radiation

    High

    May not work if pituitary is damaged — requires functional somatotrophs.

  • Those with Diabetic retinopathy

    High

    GH elevation can worsen proliferative retinopathy.

Safety & interactions

Do not use if

  • Active malignancy

    Absolute

    FDA label: discontinue if active malignancy develops. GH promotes tumor growth.

  • Disruption of hypothalamic-pituitary axis from surgery/radiation

    High

    May not work if pituitary is damaged — requires functional somatotrophs.

  • Diabetic retinopathy

    High

    GH elevation can worsen proliferative retinopathy.

General cautions

  • Pregnancy

    Absolute

    FDA label: can cause fetal harm based on mechanism of action.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Injection site reactions (most common)

    High

    EGRIFTA SV FDA label, Adverse Reactions; PMID 31611038

  • Arthralgia, pain in extremities, peripheral edema, myalgia

    Moderate

    EGRIFTA SV FDA label, Warnings (Fluid Retention) and Adverse Reactions; PMID 18057338

  • 50% develop anti-tesamorelin antibodies (no apparent efficacy impact)

    Low

    EGRIFTA SV FDA label, Immunogenicity

  • Increased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.

    Moderate

    EGRIFTA SV FDA label, Warnings (Glucose Intolerance and Diabetes Mellitus); PMID 31611038

  • Effects reverse upon cessation — requires ongoing treatment

    High

    PMID 20554713; EGRIFTA SV FDA label

  • Theoretical cancer risk with long-term GH/IGF-1 elevation

    Theoretical

    EGRIFTA SV FDA label, Warnings (Neoplasms)

  • Contraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis

    High

    EGRIFTA SV FDA label, Contraindications

Interaction summary(8)

Rated by direction with this peptide

  • Insulin and oral antidiabetic agents (metformin, sulfonylureas, etc.)

    CautionModerate

    GH-induced insulin resistance can raise glucose and HbA1c (5% vs 1% reaching HbA1c >=6.5%; HR 3.3 for incident diabetes), potentially requiring antidiabetic dose escalation and mandating glucose monitoring in treated patients.

    EGRIFTA SV FDA label, Warnings/Drug Interactions

  • Glucocorticoid replacement therapy (hydrocortisone, prednisone) in hypoadrenalism

    CautionModerate

    GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1, reducing conversion of cortisone to cortisol, so patients on glucocorticoid replacement may need their replacement or stress glucocorticoid doses increased to avoid adrenal insufficiency. This interaction is explicitly stated on the EGRIFTA SV label.

    EGRIFTA SV FDA label, Drug Interactions

  • CYP450-metabolized drugs (cyclosporine, anticonvulsants, corticosteroids, sex steroids)

    CautionLow

    The EGRIFTA label carries only a generic recommendation to monitor for potential CYP450 interactions, with no quantified clinical effect demonstrated for tesamorelin specifically (it is an inferred GH class effect). Plasma levels of narrow-therapeutic-index substrates could theoretically shift, so clinical monitoring rather than a fixed dose adjustment is advised.

    EGRIFTA SV FDA label, Drug Interactions

  • Somatropin (exogenous GH) and other GH secretagogues (e.g. ipamorelin, CJC-1295, MK-677)

    CautionTheoretical

    Combining with another agent that raises GH/IGF-1 offers no studied additive benefit and would compound the shared dose-dependent risks of fluid retention, arthralgia, insulin resistance, and IGF-1 elevation; no combination trials exist.

    Mechanism-based; no clinical data (class effects per EGRIFTA SV and somatropin labels)

  • Simvastatin and other statins used for HIV-associated dyslipidemia

    SynergisticLow

    Tesamorelin's triglyceride and cholesterol:HDL improvements were observed in phase 3 populations that already included substantial statin use, so the lipid benefit appears additive to and independent of statin therapy - though this is inferred from the trial population composition rather than a prespecified statin-interaction analysis. CYP-mediated statin level shifts remain a theoretical reason for routine monitoring.

    PMID 18057338; PMID 20554713 (inferred from population; no dedicated statin-interaction study)

  • Antiretroviral therapy (protease inhibitors, NRTIs)

    NeutralLow

    Tesamorelin was developed and trialed in patients on stable combination ART with no clinically significant pharmacokinetic interaction identified and no loss of virologic control; it does not correct ART-associated lipoatrophy of subcutaneous fat.

    PMID 18057338; PMID 20554713; EGRIFTA SV FDA label

  • GLP-1 receptor agonists (semaglutide, tirzepatide)

    ProtectiveTheoretical

    Co-administration is mechanistically attractive because GLP-1 agonists improve insulin sensitivity and could offset tesamorelin's glycemic penalty while both reduce hepatic fat, but no trial has tested the combination and the interaction remains speculative.

    Mechanism-based; no clinical trial data

  • Levothyroxine / thyroid hormone replacement

    CautionTheoretical

    GH excess increases peripheral T4-to-T3 conversion and can unmask latent central hypothyroidism, a documented somatropin class effect that has not been specifically demonstrated for tesamorelin; periodic thyroid function checks are reasonable in replaced patients.

    GH class effect (somatropin labeling); not established for tesamorelin

Known risks(7)

  • Injection site reactions (most common)

  • Arthralgia, pain in extremities, peripheral edema, myalgia

  • 50% develop anti-tesamorelin antibodies (no apparent efficacy impact)

  • Increased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.

  • Effects reverse upon cessation — requires ongoing treatment

  • Theoretical cancer risk with long-term GH/IGF-1 elevation

  • Contraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis

Drug interactions(3)

  • Cortisone/glucocorticoids

    Glucocorticoids suppress GH secretion and may reduce tesamorelin efficacy

  • Exogenous HGH

    Both elevate GH/IGF-1. Combining risks supraphysiologic levels.

  • CJC-1295

    Both are GHRH analogs. Tesamorelin is FDA-approved with stronger evidence base.

Research & benefits

Evidence base

Evidence Level
Level 1 — FDA Approved
Total Studies
30
Human Participants
1500

Two pivotal Phase III RCTs (n=806 combined) led to FDA approval 2010. Additional RCTs for NAFLD, muscle composition, cognition. 2026 meta-analysis of 5 RCTs confirmed efficacy. Long-term data to 52 weeks.

Researched for(8)

Rated by confidence in the evidence

  • Visceral fat reduction

    High

    FDA-approved indication, confirmed in two large phase 3 RCTs in HIV lipodystrophy.

    PMID 18057338 (N Engl J Med 2007;357:2359-70); PMID 20554713 (J Clin Endocrinol Metab 2010)

  • Lipid improvement

    High

    Significant triglyceride and cholesterol ratio improvements in RCTs, though LDL unchanged.

    PMID 18057338; PMID 20554713

  • Liver fat/NAFLD

    High

    Reduced liver fat and fibrosis progression in a 12-month RCT, limited to HIV cohorts.

    PMID 31611038 (Lancet HIV 2019;6:e821-30); PMID 25038357 (JAMA 2014;312:380-9)

  • Muscle composition

    Medium

    Modest lean mass gains shown in RCTs, but no proven gains in strength or function.

    PMID 18057338; PMID 20554713

  • Cognitive function

    Low

    Single small RCT in older/MCI adults suggested benefit; preliminary, never replicated.

    PMID 22869065 (Arch Neurol 2012;69:1420-9)

  • Physiologic GH restoration

    High

    RCTs confirm pulsatile GH-driven IGF-1 rise; long-term outcome edge over GH untested.

    PMID 20554713; EGRIFTA SV FDA label (DailyMed setid 3d783378-b02d-4f19-99dd-0fc91a042224)

  • Body image/QoL

    High

    Prespecified RCT patient-reported outcome improved in HIV lipodystrophy; not tested in healthy adults.

    PMID 20554713

  • Fat quality

    Speculative

    Improved fat quality is plausible but based on small substudies, not a powered trial.

    Extrapolated from PMID 31611038 (fibrosis progression) and small substudy/transcriptomic reports; no dedicated powered RCT

Benefits(8)

  • Visceral fat reduction

  • Lipid improvement

  • Liver fat/NAFLD

  • Muscle composition

  • Cognitive function

  • Physiologic GH restoration

  • Body image/QoL

  • Fat quality

Key studies(5)

  1. Falutz J et al.

    NEJM

    2007

    -15.2% VAT, triglycerides -50mg/dL in 412 patients

  2. Falutz J et al.

    J Clin Endocrinol Metab

    2010

    Sustained VAT/lipid reduction, IGF-1 +81% over 52 weeks in 806 patients

  3. Baker LD et al.

    Arch Neurol

    2012

    Improved executive function, with a nonsignificant verbal-memory trend, in 152 adults aged 55-87.

  4. Stanley TL et al.

    Lancet HIV

    2019

    -37% hepatic fat, attenuated fibrosis progression over 12 months

  5. Multiple

    Obes Res Clin Pract

    2026

    Confirmed: VAT -27.71cm2, lean mass +1.42kg, hepatic fat reduction

What research suggests over time

  • Weeks 2-4

    FDA registration trials

    IGF-1 levels rise; subjective energy and sleep quality improvements reported.

  • Months 2-3

    Falutz et al. NEJM 2007

    Visceral adipose tissue (VAT) reduction begins; trunk fat measurably lower on imaging.

  • Long-term

    Phase 3 RCT

    ~15-18% VAT reduction at 26 weeks in HIV lipodystrophy trials; effects regress on discontinuation.

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Egrifta WR (tesamorelin)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(6)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • IGF-1

    Optimal 150–250 ng/mL (adults)

    Direct marker of growth hormone axis activity — essential for tracking GH peptide effects.

    Lab normal Age-dependent (~80–280 ng/mL)

  • Fasting glucose + HbA1c

    Optimal 75–90 mg/dL

    GH peptides can affect insulin sensitivity and glucose metabolism.

    Lab normal 65–99 mg/dL

  • Fasting insulin

    Optimal 2–6 μIU/mL

    Enables HOMA-IR calculation — GH peptides can reduce insulin sensitivity.

    Lab normal 2.6–24.9 μIU/mL

  • Lipid panel

    Optimal ApoB <80, TG <80, HDL >55

    GH affects lipid metabolism; baseline needed to track changes.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

Ongoing tracking(3)

  • IGF-1

    Every 6-8 weeksOptimal 150–250 ng/mL (adults)

    Track growth hormone axis response — primary efficacy marker.

    Lab normal Age-dependent (~80–280 ng/mL)

  • Fasting glucose

    Every 4-8 weeksOptimal 75–90 mg/dL

    GH peptides can reduce insulin sensitivity.

    Lab normal 65–99 mg/dL

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic monitoring during GH axis stimulation.

    Lab normal ALT 7–56, AST 10–40 U/L

Retest schedule(6)

  1. Baseline

    critical

    Before starting

    Full baseline + IGF-1, fasting glucose, fasting insulin, lipid panel.

  2. Early follow-up

    critical

    Week 4

    Recheck IGF-1, fasting glucose, HbA1c. GH peptides commonly affect glucose handling.

  3. Second check

    critical

    Week 8

    Recheck IGF-1 trajectory and metabolic markers.

  4. Mid-protocol

    critical

    Week 12

    Comprehensive retest. IGF-1 should be in target range (150–250 ng/mL).

  5. Ongoing

    standard

    Every 6-8 weeks

    Sustained monitoring of IGF-1 and metabolic markers.

  6. Post-protocol

    standard

    4-6 weeks after stopping

    Confirm IGF-1 returns toward baseline.

When to stop and reassess(5)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • IGF-1

    stop

    Above 350 ng/mL

    Stop or reduce dose — sustained elevation carries theoretical cancer and cardiovascular risk.

  • Fasting glucose

    consult

    Consistently above 100 mg/dL (or HbA1c rising >0.3%)

    Consult a provider — GH peptides commonly reduce insulin sensitivity.

Lab monitoring helps track your body's response to Tesamorelin. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

Across 1,500+ trial patients, tesamorelin has shown benefits well beyond its FDA-approved use for HIV-related abdominal fat: improved lipids and reduced liver fat in HIV cohorts, plus preliminary cognitive findings in older adults. The 2026 five-RCT meta-analysis evaluated HIV-related body composition and metabolic outcomes, not cognition. Unlike direct GH injection, it preserves the brain's natural pulsatile release and feedback loop. Ongoing research in non-HIV populations could make it the preferred approach to age-related GH decline.

Estimated cost
About $11,030 per 28-day kit at the US cash price (Egrifta WR, Drugs.com price guide, checked 2 Nov 2026); insurance covers the approved HIV indication
FDA status
FDA-approved 2010 (Egrifta). Egrifta WR approved March 2025 (weekly preparation). Only FDA-approved medication for HIV lipodystrophy. Manufactured by Theratechnologies.
WADA status
Banned — GH secretagogue / GHRH analog under prohibited substances
Prescribability
FDA-approved as Egrifta SV/WR for excess abdominal fat in adults with HIV-associated lipodystrophy. Off-label prescribing is permitted. Tesamorelin is a biologic and is not eligible for 503A or 503B compounding exemptions.
Availability
FDA-approved Egrifta SV/WR (WR approved March 2025). Prescription treatment for excess abdominal fat in adults with HIV-associated lipodystrophy; off-label prescribing is permitted. Tesamorelin is a biologic and does not qualify for 503A or 503B compounding exemptions.

International status

  • EU

    Not EMA-approved

  • US

    FDA-approved (Egrifta)

  • Canada

    Previously Health Canada-approved; current Egrifta records are cancelled: DIN 02438712 is Cancelled Post Market and DIN 02423677 is Cancelled Pre Market.

Regulatory timeline(2)

  1. 2010
    FDA approvalEgrifta approved for HIV lipodystrophy
  2. 2025-03
    Egrifta WR approvedNew formulation prepared once weekly

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

How does it work?

Stimulates pituitary to produce GH in natural pulsatile pattern. Preserves feedback loops unlike exogenous GH.

Time to results?

4-6 weeks initial changes. 3-6 months for significant body composition improvements.

Side effects?

Injection site reactions, arthralgia, peripheral edema, myalgia. 50% develop antibodies (no efficacy impact). Modest HbA1c risk.

Only for HIV?

FDA-approved only for HIV lipodystrophy. Off-label use for NAFLD, cognitive decline, anti-aging. Insurance rarely covers off-label.